Amended claims

1. An agent comprising a terminal α-galactosyl moiety linked to a support, wherein the support is a poly-L-lysine backbone, for use in the prevention and/or treatment of an infection in a subject, wherein said infection is caused by bacteria of the gastrointestinal tract, and the infection occurs in blood, heart, cardiovascular system, liver, lung, respiratory tract, kidney, urinary tract, nervous central system, skin, subcutaneous tissues and surgical wounds.

1、一种包括末端α-半乳糖基部分连接到载体的试剂，其中所述载体是一种赖氨酸主链，用于预防和/或治疗研究对象感染，其中所述感染是由胃肠道细菌引起的，感染发生在血液、心脏、心血管系统、肝脏、肺、呼吸道、肾脏、泌尿道、中枢神经系统、皮肤、皮下组织和外科伤口。

16. A composition comprising:

(i) an agent comprising a terminal α-galactosyl moiety linked to a support, wherein the support is a poly-L-lysine backbone, and

(ii) an antibiotic.

20. The composition according to any of claims 16 to 19, wherein the agent is the random copolymer GAS914 having the following structure:



wherein n represents the average degree of polymerization, x represents the fraction of glycosylated monomer; and 1 – x represents the fraction of thioglycerol-capped monomer.

1. 根据权利要求16-19任意一项所述的组合物，其中所述试剂是具有如下结构的无规共聚物GAS914：其中n代表平均聚合度，x代表糖基化单体含量；1-x代表硫代甘油封闭单体含量。

21. A composition according to any of claims 16 to 20 for use in medicine.

21、根据权利要求16-20任意一项所述的组合物，其可用于药物。

22. A composition according to any of claims 16 to 21 for use in the prevention and/or treatment of infection caused by bacteria of the gastrointestinal tract in a subject.

22、根据权利要求16-20任意一项所述的组合物，其可用于预防和/或治疗由胃肠道细菌引起的研究对象感染。

23. The composition for use according to claim 22, wherein the bacteria of the gastrointestinal tract are enteric bacteria.

23、根据权利要求22所述应用的组合物，其中所述胃肠道细菌是肠内细菌。